Skip to content
FIND A HEALTH VALLEY ACTOR

Volumina Medical, Parithera and PeriVision win the Biopôle Startup Fund 2022

Biopôle Startup Fund winners 2022

The initiative, which includes up to CHF 90,000 of support per year for up to three consecutive years, is designed to help with the costs of rental, R&D and key services.   Volumina Medical is led by Amélie Béduer, an entrepreneur in the field of medical devices for plastic and reconstructive surgery. The team of six are…

Read More

Innosuisse: Innovation for startups

Innosuisse - startup innovation project

Competitive project funding for start-ups before market entry Innosuisse supports science-based projects of start-ups with significant innovation potential. These innovation projects must be based on application-oriented research and prepare start-ups for entering the market for the first time. In the case of projects, only the start-up is supported. No research partners are supported. Funding is…

Read More

Coaching Platinn

Platinn

Are you an entrepreneur in Western Switzerland? Are you facing challenges that prevent you from taking a step back to think long-term? Discover how Platinn coaching can help you.   Platinn is a coaching programme aimed at SMEs and start-ups in Western Switzerland. The support is based on a network of about fifty accredited coaches armed…

Read More

Biopôle Startup Fund

Biopôle Startup Fund

Up to CHF 90,000 of support per year for up to three consecutive years to help life sciences companies with the costs of rental, R&D and key services     Launched in 2021, the Biopôle’s Start-up Fund is a flagship initiative that helps the most promising life sciences ventures on campus to focus on what…

Read More

Limula and CSEM partner to automate the production of CAR T cells

CSEM + LIMULA

A Health Valley partnership to revolutionize cancer therapies and to bring a personalised treatment for cancer patients   CSEM supports Lausanne-based start-up Limula in its mission to make cell therapies more affordable. The technology developed enables the automated production of CAR T and other cell therapies at scale. The prototype is now going towards pre-industrial…

Read More

€2M Eurostars funding for a project led by Calciscon

Calciscon

CALCISCON, AMSTERDAM UNIVERSITY MEDICAL CENTERS and ADMESY have signed a collaborative agreement for the development of a laboratory benchtop analyzer for the measurement of the T50 test.   T50 is a unique test for the measurement of calcification propensity in a blood sample. The primary use of T50 is to revolutionize the treatment of patients…

Read More

Xsensio announces an agreement with Mayo Clinic

Xsensio

Xsensio Announces Know-How and Stock Purchase Agreement with Mayo Clinic   Xsensio, a Vaud-Based company that is developing the Lab-on-Skin© sensing platform, announced that it has entered into a know-how and stock purchase agreement with Mayo Clinic for the development of new wearable products based on short term health dynamics in critical care. Xsensio will…

Read More

Comphya raises CHF 850 000 in a convertible loan

CaverSTIM

Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), announced the fundraising of CHF 850k in a convertible loan. This brings the total amount of funds raised to CHF 5.1 Mio.   The financial round included investment from existing shareholders and additional investors. Praxis Spinal Cord Institute, a non-profit organization, also committed…

Read More

Research is less profitable for the pharmaceutical industry

Pills ©maksim goncharenok

According to a Deloitte study, investing in research is less and less interesting. The audit and consulting firm used figures from the world’s 20 largest pharmaceutical companies, including the Swiss companies Novartis and Roche.   In 2022, the world’s twenty largest pharmaceutical companies spent 130 billion francs on research and development. This sum has fallen…

Read More

Lonza invested CHF 1 billion in Visp in 2022

Ibex™ Lonza facilit in Visp Switzerland

The biopharmaceutical company employs 5,000 people in Valais, and also announced a 15% sales growth in 2022, representing a total of CHF 6.2 billion   Lonza has invested one billion francs in Visp (VS) and half a billion in Stein (AG) in 2022, according to the chairman of the group’s board of directors, Albert Baehni. Some…

Read More